Table 1.
Absolute CIN3+ risks for single and combined triage tests.
| Test result | N | CIN3+ (n) | Absolute CIN3+ risk | 95% CI |
|---|---|---|---|---|
| Single triage strategies | ||||
| Methylation + | 121 | 40 | 33.1% | (24.7–41.4%) |
| Methylation − | 173 | 17 | 9.8% | (5.4–14.3%) |
| HPV16/18 + | 127 | 35 | 27.6% | (19.8–35.3%) |
| HPV16/18 − | 167 | 22 | 13.2% | (8.0–18.3%) |
| HPV16/18/31/33/45 + | 195 | 48 | 24.6% | (18.6–30.7%) |
| HPV16/18/31/33/45 − | 99 | 9 | 9.1% | (3.4–14.8%) |
| Combined triage strategies | ||||
| HPV16/18 + and methylation + | 62 | 25 | 40.3% | (28.1–52.5%) |
| HPV16/18 + and methylation − | 65 | 10 | 15.4% | (6.6–24.2%) |
| HPV16/18 − and methylation + | 59 | 15 | 25.4% | (14.3–36.5%) |
| HPV16/18 − and methylation − | 108 | 7 | 6.5% | (1.8–11.1%) |
| HPV16/18/31/33/45 + and methylation + | 94 | 33 | 35.1% | (25.5–44.8%) |
| HPV16/18/31/33/45 + and methylation − | 101 | 15 | 14.9% | (7.9–21.8%) |
| HPV16/18/31/33/45 − and methylation + | 27 | 7 | 25.9% | (9.4–42.5%) |
| HPV16/18/31/33/45 − and methylation − | 72 | 2 | 2.8% | (0–6.6%) |
N, group total; n, number of CIN3+ detected; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; 95% CI, 95% confidence interval; +, positive; −, negative.